vTv Therapeutics is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company. Co.'s pipeline include its programs for the treatment of type 1 diabetes (TTP399) and for psoriasis (HPP737). Co. is conducting a Phase 1 mechanistic study of TTP399 in patients with type 1 diabetes to determine the impact of TTP399 on ketone body formation during a period of acute insulin withdrawal. Co. is also conducting Phase 1 study of HPP737, an orally administered phosphodiesterase type 4 inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as part of its psoriasis program. The VTVT stock yearly return is shown above.
The yearly return on the VTVT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VTVT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|